Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients

被引：0
|
作者：
Aye, T. T. [1 ]
Mon, S. [1 ]
Khine, M. [2 ]
Sein, N. [2 ]
Thant, N. M. [2 ]
Win, A. K. [2 ]
Aung, E. P. P. [2 ]
Hnin, P. T. [2 ]
机构：
[1] Bahosi Med Ctr, Med Oncol, Bahosi Housing Complex, Yangon, Myanmar
[2] Thurein Mon Clin, Med Oncol, Yangon, Myanmar
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [2] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
    Jia, W.
    Wang, T. Z.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555
  • [3] Cardiotoxicity of trastuzumab adjuvant treatment in positive HER2 breast cancer
    Piotrowski, G.
    Gawor, R.
    Potemski, P.
    Gawor, Z.
    EUROPEAN HEART JOURNAL, 2013, 34 : 831 - 832
  • [4] Cardiotoxicity in HER2 positive breast cancer patients treated with trastuzumab
    Lopez, M.
    Minguito Carazo, C.
    Delgado Sillero, I.
    Rojas Piedra, M.
    Tavara Silva, B.
    Lopez-Gonzalez, A.
    Castanon Lopez, C.
    Nieto Mangudo, B.
    Pedraza Lorenzo, M.
    Rodriguez Sanchez, A.
    Diz Tain, P.
    De Sande Gonzalez, L. M.
    Medina Valdivieso, S.
    Lopez Gonzalez, L.
    Honrado Franco, E.
    Garcia-Palomo, A.
    Sanchez-Cousido, L. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S332 - S332
  • [5] Treatment of HER2 positive breast cancer patients
    Matos, Erika
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2012, 81 (03): : 236 - 245
  • [6] Impact of HER2 Copy Number in IHC HER2 2+/FISH Positive Breast Cancer on Outcome of Adjuvant Trastuzumab Treatment
    Borley, A.
    Mercer, T.
    Morgan, M.
    Barrett-Lee, P.
    Jasani, B.
    JOURNAL OF PATHOLOGY, 2013, 231 : 19 - 19
  • [7] Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab
    Van Asten, K.
    Jongen, L.
    Beuselinck, B.
    Laenen, A.
    Wildiers, H.
    Poppe, A.
    Floriss, G.
    Christiaens, M.
    Neven, P.
    BREAST, 2015, 24 : S119 - S119
  • [8] POPULATION BASED OUTCOME OF HER2 POSITIVE EARLY BREAST CANCER IN TRASTUZUMAB ERA
    Matos, E.
    Kuhar, C. Grasic
    Zakotnik, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 112 - 113
  • [9] Risk factors and clinical relevance of cardiotoxicity in her2 positive breast cancer patients treated with trastuzumab
    Minguito Carazo, C. Carlos
    Lopez Flores, M.
    Sanchez Cousido, L. F.
    Lopez Gonzalez, A.
    Rodriguez Santamarta, M.
    Tundidor Sanz, E.
    Echarte Morales, J.
    Sanchez Munoz, E.
    Garcia Palomo, A.
    Fernandez Vazquez, F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 37 - 37
  • [10] Single institute experience of treatment for metastatic HER2 positive breast cancer patients with trastuzumab deruxtecan
    Kojima, Yasuyuki
    Tsugawa, Koichiro
    ANNALS OF ONCOLOGY, 2021, 32 : S338 - S338
12345